



Drugs for Neglected Diseases *initiative*

72nd World Health Assembly

DNDi Intervention on **Agenda Item 11.7 Access to Medicines and Vaccines**

DNDi welcomes the implementation Roadmap. Our experience is aligned with its approach, to integrate considerations of access throughout the R&D process. We support further work on regulatory pathways.

Transparency on costs of R&D is a central element of DNDi's policy. We put as much information into the public domain as possible, including all clinical trial data, our actual R&D costs and related financing flows, including the in-kind contributions from our partners where they provide them.

We consider transparency important to:

- 1) Advance scientific knowledge – progress is based on openness and collaborative practices
- 2) Demonstrate value for money of investments by our public and private funders
- 3) Incentivize further funding for public and private investment in R&D and inform new public funding policies

Discussions around costing must of course be sophisticated, taking into account different business models, portfolios and technologies. Nevertheless, transparency remains for us a matter of public accountability for any institution seeking the benefit of public support and claiming to be engaged in supporting the SDGs.